Skip to content
Mytos logo — Scaling Regenerative Medicines to Millions of Patients

Mytos

Scaling Regenerative Medicines to Millions of Patients

Founded 2016 United Kingdom London, United Kingdom 48 employees Series A Total: $20.93M

General Information

Company Name Mytos
Founded Year 2016
Location United Kingdom London, United Kingdom
Employees 48
Funding Stage Series A
Business Model B2B, White Label, B2B2C
Revenue Model Service Fee, Project Based, Usage Based
Offices as of Sep 2026
London, United Kingdom
Social

BounceWatch is an independent company data service, not affiliated with Mytos. To contact Mytos, visit mytos.bio.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Mytos compare?

A PDF of Mytos and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Mytos soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Mytos

Mytos, founded in 2016 and headquartered in the United Kingdom, is at the forefront of scaling regenerative medicines to millions of patients. Their innovative iDEM robotics platform sits at the heart of a cutting-edge automated CDMO process, aiming to provide stem cell-derived therapies at a low cost.

The company has secured partnerships targeting various critical medical areas, including treating Parkinson's with neurons, repairing bones, restoring sight with corneal cells, and addressing hearing loss with auditory neurons. By 2027, Mytos anticipates its products will be entering clinical applications.

Having raised over $24M to date, including a recent $19M Series A round from investors such as Buckley Ventures, IQ Capital, and Wing Venture Capital, Mytos connects with influential founders from companies like Kite, Sana, Dropbox, and Revolut. The company's team is composed of elite engineers, alongside Nature-published scientists, driving innovation in biotechnology. Currently, Mytos is actively hiring to support its growth trajectory.

Business keywords: Regenerative Medicine, Stem Cell Therapy, Automated Manufacturing, iDEM Robotics Platform, CDMO (Contract Development and Manufacturing Organization), Parkinson's Treatment, Bone Repair, Blindness Treatment, Hearing Loss Treatment, Biotech Engineering, Hardware Development, Software Development, Mechanical Engineering

Services & Products

Automated manufacturing of regenerative medicine products
Process & Analytical Development
Regulatory Support
Cost-efficient production solutions

Target Customers

Biotech companies Clinical-stage pharmaceutical companies Research institutions working on regenerative medicine

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $19.00M 3
Buckley Ventures, IQ Capital +1
01 Nov 2023
Round Undisclosed 1
TBD Angels
01 Jul 2022
Seed Undisclosed -
01 Jan 2019
Seed $1.80M 5
Y Combinator, Acequia Capital +3
01 Aug 2018
Seed $130.00K 1
Y Combinator
01 Jan 2018

Mytos Alternatives & Competitors

Mytos vs
Fortuna Fix
Fortuna Fix United Kingdom

Reprogram and regenerate. A revolution in medicine.

Series B
1 employees
Biotechnology, Pharmaceutical
Mytos vs
MICA Biosystems
MICA Biosystems United Kingdom

An innovative and dynamic biotech start-up, unlocking the potential of stem cells and nanotechnology...

Grant
9 employees
Biotechnology, Health Care

FAQ About Mytos

Scaling Regenerative Medicines to Millions of Patients
Mytos was founded in 2016.
Mytos is headquartered in London, United Kingdom.
Mytos has a B2B, White Label and B2B2C business model. Its revenue comes from Service Fee, Project Based and Usage Based.
Mytos has approximately 48 employees.
Mytos has completed 5 funding rounds, raising a total of $20.93M. The latest funding stage is Series A.
Mytos offers: Automated manufacturing of regenerative medicine products, Process & Analytical Development, Regulatory Support, Cost-efficient production solutions.
Top alternatives and competitors to Mytos include Fortuna Fix, MICA Biosystems. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Mytos and Fortuna Fix are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Mytos, https://bouncewatch.com/company/mytos, updated 18 May 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout